EVIA Life Sciences Inc.
About EVIA Life Sciences Inc.
EVIA Life Sciences is an early-stage biotechnology company pioneering the development of extracellular vesicle (EV) and exosome-based therapeutics derived from its proprietary cell-reprogramming technology. The company's foundational platform chemically reprograms mature hepatocytes into proliferative, non-genetically modified human chemically induced liver progenitor cells (hCLiPs). These progenitor cells serve as a scalable, high-yield source for producing potent EVs containing therapeutic payloads. EVIA's research is supported by an extensive intellectual property portfolio, peer-reviewed scientific publications and collaborations with leading academic and medical institutions in Japan.
Investors
Not disclosed in the source filing. Form D filings do not list investors — StreetZero surfaces them from news where available.
Key highlights
- EVIA Life Sciences develops EV and exosome therapeutics from proprietary hCLiP cell-reprogramming technology.
- Platform uses chemically reprogrammed hepatocytes as a scalable source for potent therapeutic vesicles.
- Company maintains IP portfolio and academic collaborations primarily in Japan.
- Completed $700k private placement with undisclosed investors.
Ask StreetZero about EVIA Life Sciences Inc.
Put our AI to work on this deal.
Similar companies
Other Biotechnology deals, ranked by Signal.
Source document & SEC filing
The source SEC filing and the cached document are available to members only. Sign in to view and download them.
Sign in to view the filing Create free account